Literature DB >> 20073037

Rare genetic causes of autosomal dominant or recessive hypercholesterolaemia.

Anne K Soutar1.   

Abstract

Familial hypercholesterolaemia (FH) is a human inherited disorder of metabolism characterised by increased serum low-density lipoprotein (LDL) cholesterol. It is caused by defects in the LDL-receptor pathway that impair normal uptake and clearance of LDL by the liver. The commonest cause of FH is mutations in LDLR, the gene for the LDL receptor, but defects also occur in APOB that encodes its major protein ligand. More recently, defects in two other genes, LDLRAP1 and PCSK9, have been found in patients with FH and investigation of these has shed new light on the functioning and complexity of the LDL receptor pathway. Cells from patients with autosomal recessive hypercholesterolaemia (ARH) fail to internalise the LDL receptor because they carry two defective alleles of LDLRAP1, a gene that encodes a specific clathrin adaptor protein. PCSK9 encodes proprotein convertase subtilisin kexin type 9, a secreted protein that binds to the LDL receptor and promotes its degradation. Gain-of function mutations in PCSK9 are autosomal dominant and cause hypercholesterolaemia because they increase the affinity of PCSK9 protein for the LDL receptor, whereas loss-of-function mutations reduce serum cholesterol because LDL-receptor protein is exposed to reduced PCSK9-mediated degradation. Thus, PCSK9 has become a new target for cholesterol-lowering drug therapy. (c) 2010 IUBMB IUBMB Life.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20073037     DOI: 10.1002/iub.299

Source DB:  PubMed          Journal:  IUBMB Life        ISSN: 1521-6543            Impact factor:   3.885


  6 in total

1.  An improved method on stimulated T-lymphocytes to functionally characterize novel and known LDLR mutations.

Authors:  Maria Romano; Maria Donata Di Taranto; Peppino Mirabelli; Maria Nicoletta D'Agostino; Arcangelo Iannuzzi; Gennaro Marotta; Marco Gentile; Maddalena Raia; Rosa Di Noto; Luigi Del Vecchio; Paolo Rubba; Giuliana Fortunato
Journal:  J Lipid Res       Date:  2011-08-24       Impact factor: 5.922

2.  Regulation and deregulation of cholesterol homeostasis: The liver as a metabolic "power station".

Authors:  Laura Trapani; Marco Segatto; Valentina Pallottini
Journal:  World J Hepatol       Date:  2012-06-27

3.  Association of genetic variants influencing lipid levels with coronary artery disease in Japanese individuals.

Authors:  Fumihiko Takeuchi; Masato Isono; Tomohiro Katsuya; Mitsuhiro Yokota; Ken Yamamoto; Toru Nabika; Kazuro Shimokawa; Eitaro Nakashima; Takao Sugiyama; Hiromi Rakugi; Shuhei Yamaguchi; Toshio Ogihara; Yukio Yamori; Norihiro Kato
Journal:  PLoS One       Date:  2012-09-26       Impact factor: 3.240

4.  Variable expressivity and co-occurrence of LDLR and LDLRAP1 mutations in familial hypercholesterolemia: failure of the dominant and recessive dichotomy.

Authors:  Akl C Fahed; Ruby Khalaf; Rony Salloum; Rabih R Andary; Raya Safa; Inaam El-Rassy; Elie Moubarak; Sami T Azar; Fadi F Bitar; Georges Nemer
Journal:  Mol Genet Genomic Med       Date:  2016-02-24       Impact factor: 2.183

5.  Variable phenotypic expression of nonsense mutation p.Thr5* in the APOE gene.

Authors:  Trond P Leren; Thea Bismo Strøm; Knut Erik Berge
Journal:  Mol Genet Metab Rep       Date:  2016-10-25

6.  Stakeholder Views on Active Cascade Screening for Familial Hypercholesterolemia.

Authors:  Carla G van El; Valentina Baccolini; Peter Piko; Martina C Cornel
Journal:  Healthcare (Basel)       Date:  2018-08-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.